|
1
|
Stinchcombe TE and Socinski MA: Treatment
paradigms for advanced stage non-small cell lung cancer in the era
of multiple lines of therapy. J Thorac Oncol. 4:243–250. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lemke G: Biology of the TAM receptors.
Cold Spring Harb Perspect Biol. 5:a0090762013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lemke G and Rothlin CV: Immunobiology of
the TAM receptors. Nat Rev Immunol. 8:327–336. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lemke G and Burstyn-Cohen T: TAM receptors
and the clearance of apoptotic cells. Ann NY Acad Sci. 1209:23–29.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagata K, Ohashi K, Nakano T, Arita H,
Zong C, Hanafusa H and Mizuno K: Identification of the product of
growth arrest-specific gene 6 as a common ligand for Axl, Sky, and
Mer receptor tyrosine kinases. J Biol Chem. 271:30022–30027. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Braunger J, Schleithoff L, Schulz AS,
Kessler H, Lammers R, Ullrich A, Bartram CR and Janssen JW:
Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is
mediated mainly by a multi-substrate docking-site. Oncogene.
14:2619–2631. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sasaki T, Knyazev PG, Clout NJ, Cheburkin
Y, Göhring W, Ullrich A, Timpl R and Hohenester E: Structural basis
for Gas6-Axl signalling. EMBO J. 25:80–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Bryan JP, Frye RA, Cogswell PC, Neubauer
A, Kitch B, Prokop C, Espinosa R III, Le Beau MM, Earp HS and Liu
ET: axl, a transforming gene isolated from primary human myeloid
leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell
Biol. 11:5016–5031. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rochlitz C, Lohri A, Bacchi M, Schmidt M,
Nagel S, Fopp M, Fey MF, Herrmann R and Neubauer A: Axl expression
is associated with adverse prognosis and with expression of Bcl-2
and CD34 in de novo acute myeloid leukemia (AML): Results from a
multicenter trial of the Swiss Group for Clinical Cancer Research
(SAKK). Leukemia. 13:1352–1358. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Berclaz G, Altermatt HJ, Rohrbach V,
Kieffer I, Dreher E and Andres AC: Estrogen dependent expression of
the receptor tyrosine kinase axl in normal and malignant human
breast. Ann Oncol. 12:819–824. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Craven RJ, Xu LH, Weiner TM, Fridell YW,
Dent GA, Srivastava S, Varnum B, Liu ET and Cance WG: Receptor
tyrosine kinases expressed in metastatic colon cancer. Int J
Cancer. 60:791–797. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nemoto T, Ohashi K, Akashi T, Johnson JD
and Hirokawa K: Overexpression of protein tyrosine kinases in human
esophageal cancer. Pathobiology. 65:195–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rankin EB, Fuh KC, Taylor TE, Krieg AJ,
Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ: AXL is
an essential factor and therapeutic target for metastatic ovarian
cancer. Cancer Res. 70:7570–7579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sainaghi PP, Castello L, Bergamasco L,
Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in
prostate carcinoma cell lines expressing the Axl receptor. J Cell
Physiol. 204:36–44. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ito T, Ito M, Naito S, Ohtsuru A, Nagayama
Y, Kanematsu T, Yamashita S and Sekine I: Expression of the Axl
receptor tyrosine kinase in human thyroid carcinoma. Thyroid.
9:563–567. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Byers LA, Diao L, Wang J, Saintigny P,
Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al: An
epithelial-mesenchymal transition gene signature predicts
resistance to EGFR and PI3K inhibitors and identifies Axl as a
therapeutic target for overcoming EGFR inhibitor resistance. Clin
Cancer Res. 19:279–290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Asiedu MK, Beauchamp-Perez FD, Ingle JN,
Behrens MD, Radisky DC and Knutson KL: AXL induces
epithelial-to-mesenchymal transition and regulates the function of
breast cancer stem cells. Oncogene. 33:1316–1324. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu F, Li J, Jang C, Wang J and Xiong J:
The role of Axl in drug resistance and epithelial-to-mesenchymal
transition of non-small cell lung carcinoma. Int J Clin Exp Pathol.
7:6653–6661. 2014.PubMed/NCBI
|
|
19
|
Brand TM, Iida M, Stein AP, Corrigan KL,
Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP,
et al: AXL is a logical molecular target in head and neck squamous
cell carcinoma. Clin Cancer Res. 21:2601–2612. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wimmel A, Glitz D, Kraus A, Roeder J and
Schuermann M: Axl receptor tyrosine kinase expression in human lung
cancer cell lines correlates with cellular adhesion. Eur J Cancer.
37:2264–2274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shieh YS, Lai CY, Kao YR, Shiah SG, Chu
YW, Lee HS and Wu CW: Expression of axl in lung adenocarcinoma and
correlation with tumor progression. Neoplasia. 7:1058–1064. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK,
Yoon SJ, Park BM, Park E, Bae JH, Choi CM, et al: MET and AXL
inhibitor NPS-1034 exerts efficacy against lung cancer cells
resistant to EGFR kinase inhibitors because of MET or AXL
activation. Cancer Res. 74:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ye X, Li Y, Stawicki S, Couto S,
Eastham-Anderson J, Kallop D, Weimer R, Wu Y and Pei L: An anti-Axl
monoclonal antibody attenuates xenograft tumor growth and enhances
the effect of multiple anticancer therapies. Oncogene.
29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J,
Kallop D, Ludlam MJ and Pei L: Axl as a potential therapeutic
target in cancer: Role of Axl in tumor growth, metastasis and
angiogenesis. Oncogene. 28:3442–3455. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen QY, Xu LQ, Jiao DM, Yao QH, Wang YY,
Hu HZ, Wu YQ, Song J, Yan J and Wu LJ: Silencing of Rac1 modifies
lung cancer cell migration, invasion and actin cytoskeleton
rearrangements and enhances chemosensitivity to antitumor drugs.
Int J Mol Med. 28:769–776. 2011.PubMed/NCBI
|
|
27
|
Gastonguay A, Berg T, Hauser AD, Schuld N,
Lorimer E and Williams CL: The role of Rac1 in the regulation of
NF-κB activity, cell proliferation, and cell migration in non-small
cell lung carcinoma. Cancer Biol Ther. 13:647–656. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scheibenbogen C, Möhler T, Haefele J,
Hunstein W and Keilholz U: Serum interleukin-8 (IL-8) is elevated
in patients with metastatic melanoma and correlates with tumour
load. Melanoma Res. 5:179–181. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Browne A, Sriraksa R, Guney T, Rama N, Van
Noorden S, Curry E, Gabra H, Stronach E and El-Bahrawy M:
Differential expression of IL-8 and IL-8 receptors in benign,
borderline and malignant ovarian epithelial tumours. Cytokine.
64:413–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim SJ, Uehara H, Karashima T, Mccarty M,
Shih N and Fidler IJ: Expression of interleukin-8 correlates with
angiogenesis, tumorigenicity, and metastasis of human prostate
cancer cells implanted orthotopically in nude mice. Neoplasia.
3:33–42. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL and
Li LZ: Autocrine production of interleukin-8 confers cisplatin and
paclitaxel resistance in ovarian cancer cells. Cytokine.
56:365–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stronach EA, Cunnea P, Turner C, Guney T,
Aiyappa R, Jeyapalan S, de Sousa CH, Browne A, Magdy N, Studd JB,
et al: The role of interleukin-8 (IL-8) and IL-8 receptors in
platinum response in high grade serous ovarian carcinoma.
Oncotarget. 6:31593–31603. 2015.PubMed/NCBI
|
|
33
|
Duan Z, Feller AJ, Penson RT, Chabner BA
and Seiden MV: Discovery of differentially expressed genes
associated with paclitaxel resistance using cDNA array technology:
Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic
protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res.
5:3445–3453. 1999.PubMed/NCBI
|
|
34
|
Fernando RI, Hamilton DH, Dominguez C,
David JM, McCampbell KK and Palena C: IL-8 signaling is involved in
resistance of lung carcinoma cells to erlotinib. Oncotarget.
7:42031–4204. 2016.PubMed/NCBI
|
|
35
|
Liu YN, Chang TH, Tsai MF, Wu SG, Tsai TH,
Chen HY, Yu SL, Yang JC and Shih JY: IL-8 confers resistance to
EGFR inhibitors by inducing stem cell properties in lung cancer.
Oncotarget. 6:10415–10431. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Giles KM, Kalinowski FC, Candy PA, Epis
MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ and Leedman PJ: Axl
mediates acquired resistance of head and neck cancer cells to the
epidermal growth factor receptor inhibitor erlotinib. Mol Cancer
Ther. 12:2541–2558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gong J, Morishita A, Kurokohchi K, Tani J,
Kato K, Miyoshi H, Inoue H, Kobayashi M, Liu S, Murota M, et al:
Use of protein array to investigate receptor tyrosine kinases
activated in gastric cancer. Int J Oncol. 36:101–106.
2010.PubMed/NCBI
|
|
38
|
Tu SH, Ho CT, Liu MF, Huang CS, Chang HW,
Chang CH, Wu CH and Ho YS: Luteolin sensitises drug-resistant human
breast cancer cells to tamoxifen via the inhibition of cyclin E2
expression. Food Chem. 141:1553–1561. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chian S, Li YY, Wang XJ and Tang XW:
Luteolin sensitizes two oxaliplatin-resistant colorectal cancer
cell lines to chemotherapeutic drugs via inhibition of the Nrf2
pathway. Asian Pac J Cancer Prev. 15:2911–2916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qu Q, Qu J, Guo Y, Zhou BT and Zhou HH:
Luteolin potentiates the sensitivity of colorectal cancer cell
lines to oxaliplatin through the PPARγ/OCTN2 pathway. Anticancer
Drugs. 25:1016–1027. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin Y, Shi R, Wang X and Shen HM:
Luteolin, a flavonoid with potential for cancer prevention and
therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hutterer M, Knyazev P, Abate A, Reschke M,
Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, et
al: Axl and growth arrest-specific gene 6 are frequently
overexpressed in human gliomas and predict poor prognosis in
patients with glioblastoma multiforme. Clin Cancer Res. 14:130–138.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gustafsson A, Martuszewska D, Johansson M,
Ekman C, Hafizi S, Ljungberg B and Dahlbäck B: Differential
expression of Axl and Gas6 in renal cell carcinoma reflecting tumor
advancement and survival. Clin Cancer Res. 15:4742–4749. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ryou SM, Kim JM, Yeom JH, Hyun S, Kim S,
Han MS, Kim SW, Bae J, Rhee S and Lee K: Gold nanoparticle-assisted
delivery of small, highly structured RNA into the nuclei of human
cells. Biochem Biophys Res Commun. 416:178–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rosi NL, Giljohann DA, Thaxton CS,
Lytton-Jean AK, Han MS and Mirkin CA: Oligonucleotide-modified gold
nanoparticles for intracellular gene regulation. Science.
312:1027–1030. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Araki S, Omori Y, Lyn D, Singh RK,
Meinbach DM, Sandman Y, Lokeshwar VB and Lokeshwar BL:
Interleukin-8 is a molecular determinant of androgen independence
and progression in prostate cancer. Cancer Res. 67:6854–6862. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Luppi F, Longo AM, de Boer WI, Rabe KF and
Hiemstra PS: Interleukin-8 stimulates cell proliferation in
non-small cell lung cancer through epidermal growth factor receptor
transactivation. Lung Cancer. 56:25–33. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheng D, Kong H and Li Y: Prognostic value
of interleukin-8 and MMP-9 in nasopharyngeal carcinoma. Eur Arch
Otorhinolaryngol. 271:503–509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Levin PA, Brekken RA, Byers LA, Heymach JV
and Gerber DE: Axl receptor axis: A new therapeutic target in lung
cancer. J Thorac Oncol. 11:1357–1362. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shi J and Wei PK: Interleukin-8: A potent
promoter of angiogenesis in gastric cancer. Oncol Lett.
11:1043–1050. 2016.PubMed/NCBI
|
|
52
|
Lin Y, Huang R, Chen L, Li S, Shi Q,
Jordan C and Huang RP: Identification of interleukin-8 as estrogen
receptor-regulated factor involved in breast cancer invasion and
angiogenesis by protein arrays. Int J Cancer. 109:507–515. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kubo F, Ueno S, Hiwatashi K, Sakoda M,
Kawaida K, Nuruki K and Aikou T: Interleukin 8 in human
hepatocellular carcinoma correlates with cancer cell invasion of
vessels but not with tumor angiogenesis. Ann Surg Oncol.
12:800–807. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Long X, Ye Y, Zhang L, Liu P, Yu W, Wei F,
Ren X and Yu J: IL-8, a novel messenger to cross-link inflammation
and tumor EMT via autocrine and paracrine pathways (Review). Int J
Oncol. 48:5–12. 2016.PubMed/NCBI
|
|
55
|
Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ,
Zhou SL, Zhao YM, Xiao YS, Sun QM, Ding ZB, et al:
Macrophage-secreted IL-8 induces epithelial-mesenchymal transition
in hepatocellular carcinoma cells by activating the
JAK2/STAT3/Snail pathway. Int J Oncol. 46:587–596. 2015.PubMed/NCBI
|
|
56
|
Duan Z, Lamendola DE, Penson RT, Kronish
KM and Seiden MV: Overexpression of IL-6 but not IL-8 increases
paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine.
17:234–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Maheshwari A, Lu W, Guida WC, Christensen
RD and Calhoun DA: IL-8/CXC ligand 8 survives neonatal gastric
digestion as a result of intrinsic aspartyl proteinase resistance.
Pediatr Res. 57:438–444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zuco V, Cassinelli G, Cossa G, Gatti L,
Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V,
Cincinelli R, et al: Targeting the invasive phenotype of
cisplatin-resistant non-small cell lung cancer cells by a novel
histone deacetylase inhibitor. Biochem Pharmacol. 94:79–90. 2015.
View Article : Google Scholar : PubMed/NCBI
|
